Kinfo
Alto Neuroscience Inc. logo

Alto Neuroscience Inc.

ANRONYSEHealthcare·US · USD
$28.03
+1.55 (+5.85%)
Prices as of July 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap983.68M USD
Enterprise value688.74M USD
Trailing P/E-12.80
Forward P/E-8.16
PEG ratio-0.30
Price / sales0.00
Price / book4.04
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-21.71%
Return on equity-38.86%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-77.15M USD
Net income-74.31M USD
Diluted EPS-$2.43
Rev. growth (YoY)0.00%
Balance sheet
Total cash263.76M USD
Total debt23.21M USD
Debt / equity9.54
Current ratio20.52
Book value / share$6.94
Cash flow (TTM)
Operating cash flow-62.30M USD
Levered free cash flow-40.37M USD
Shares & price
Shares outstanding35.05M
Float23.66M
Held by institutions82.09%
Beta1.07
50-day MA$23.00
200-day MA$17.88
52-week high$28.44
52-week low$2.53
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-13-0.50-0.80−60.00%2026-04-171.001.09+9.00%2026-03-16-0.51-0.45+11.76%2026-01-164.474.67+4.47%
About Alto Neuroscience Inc.

Alto Neuroscience Inc. is a biotechnology company that focuses on developing precision therapeutics for psychiatric disorders. The company's primary objective is to utilize advanced neurobiological insights and digital tools to tailor treatments for conditions like depression, anxiety, and other mental health disorders. Utilizing cutting-edge techniques such as AI-driven patient profiling and biomarker-based approaches, Alto Neuroscience seeks to enhance the efficacy of mental health treatments by ensuring more personalized and targeted solutions. This approach represents a significant innovation in the mental health sector by moving away from the one-size-fits-all model of psychotropic medications. In terms of market impact, Alto Neuroscience operates at the intersection of biotechnology and digital health, playing a pivotal role in the evolution of psychiatric treatment paradigms. The company's efforts contribute to the broader healthcare landscape by potentially improving patient outcomes and reducing trial and error in mental health medication management.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Amit Etkin M.D., Ph.D.
Employees
68
Headquarters
Mountain View, CA, United States

Frequently asked questions about Alto Neuroscience Inc.